Subgroup analyses of the phase 3 RASolute 302 trial showed overall survival favored daraxonrasib over chemotherapy in metastatic pancreatic cancer.

Futibatinib, pemigatinib, and lirafugratinib showed similar response rates and progression-free survival at first FGFR inhibitor exposure in biliary tract cancers with FGFR alterations.

Frontline iza-bren plus pembrolizumab yielded a 57.9% ORR in recurrent or metastatic HNSCC at 2.5 mg/kg, the dose chosen for phase 3 study.

In the real-world CEMI-LUNG study, first-line cemiplimab produced survival and response outcomes consistent with the pivotal EMPOWER-Lung 1 trial.

Data from the phase 3 OptiTROP-Lung06 trial may support sacituzumab tirumotecan plus pembrolizumab as a new frontline option for this NSCLC population.

Catch up on 5 melanoma and skin cancer readouts from ESMO 2026, including NADINA, OptimUM-01, OptimUM-09, C-POST, and KEYNOTE-630.

ESMO 2026 posters showed durable EV-302 benefit in older and comorbid populations plus persistent early mortality in metastatic urothelial carcinoma.

A post hoc ReFocus analysis found prior immune checkpoint inhibitor exposure raised the risk of mucocutaneous AEs with lirafugratinib.